Krystal Biotech
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
$351.46
After-hours close+0.18 (+0.05%)
At close$351.28(−1.73%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 133.40%Insiders 19.96%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 29.48M · Float 23.51M · 79.8% free float
Institutions13F, as of Jun 30, 2026
440 holders · 39.33M shares · 95 new positions · 272 increased · 111 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 4.42M | 14.99% | +44.2K | Aug 13, 2026 |
| BlackRock, Inc. | 4.18M | 14.18% | +241.0K | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 2.89M | 9.80% | 0 | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 1.57M | 5.34% | +118.2K | Aug 13, 2026 |
| State Street Corp | 1.35M | 4.58% | +36.7K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.24M | 4.21% | +75.2K | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 939.3K | 3.19% | −213.8K | Aug 11, 2026 |
| Capital World Investors | 777.8K | 2.64% | −46.9K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Krish S. Krishnanincl. Suma M. Krishnan | 11.50% | 3.39M | 13G | May 4, 2026 ↗ |
| State Street Corporation | 5.10% | 1.45M | Oct 16, 2024 ↗ | |
| Vanguard Portfolio Management | 5.05% | 1.48M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Krish S. Krishnan | director, 10 percent owner, officer: President and CEO | 2.88M | 9.76% | Jun 5, 2026 |
| Suma Krishnan | director, 10 percent owner, officer: President, R&D | 2.86M | 9.70% | Jun 5, 2026 |
| Daniel Janney | director | 73.3K | 0.25% | Mar 3, 2026 |
| Dino A. Rossi | director | 50.0K | 0.17% | Aug 14, 2026 |
| Kathryn Romano | officer: Chief Accounting Officer | 22.4K | 0.08% | Mar 3, 2026 |
| Laurent Louis Jean Goux | officer: EVP, Head of International | 919 | 0.00% | Mar 6, 2026 |
3 people have not refiled in the last 18 months (18.2K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Dino A. Rossidirector | Sale · 8 lots | 25,000 | $329.12 | 50,000 |
| Jun 25, 2026 | John Charles Thomasofficer: EVP, General Counsel | Sale | 1,000 | $347.27 | 0 |
| Jun 4, 2026 | Krish S. Krishnandirector, 10 percent owner, officer: President and CEO | Sale · 11 lots | 25,000 | $308.12 | 1,450,253 |
| Jun 4, 2026 | Suma Krishnandirector, 10 percent owner, officer: President, R&D | Sale · 11 lots | 25,000 | $308.11 | 1,378,155 |
| May 26, 2026 | John Charles Thomasofficer: EVP, General Counsel | Sale | 642 | $302.03 | 0 |
| Mar 4, 2026 | Krish S. Krishnandirector, 10 percent owner, officer: President and CEO | Sale · 10 lots | 25,000 | $263.17 | 1,475,253 |
| Mar 4, 2026 | Suma Krishnandirector, 10 percent owner, officer: President, R&D | Sale · 10 lots | 25,000 | $263.21 | 1,403,155 |
| Feb 27, 2026 | Daniel Janneydirector | Sale · 2 lots | 11,803 | $275.59 | 73,293 |
| Mar 2, 2026 | Kathryn Romanoofficer: Chief Accounting Officer | Sale | 750 | $267.60 | 22,366 |
| Feb 24, 2026 | Daniel Janneydirector | Sale · 17 lots | 51,720 | $267.27 | 93,537 |
CongressHouse and Senate disclosures
Not reported.